+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Transfusion Diagnostics Market - Global Forecast to 2030- Product Image
Blood Transfusion Diagnostics Market - Global Forecast to 2030- Product Image
Sale

Blood Transfusion Diagnostics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010986
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Blood Transfusion Diagnostics Market grew from USD 3.86 billion in 2024 to USD 4.25 billion in 2025. It is expected to continue growing at a CAGR of 9.83%, reaching USD 6.77 billion by 2030.

Blood transfusion diagnostics serve as the cornerstone of modern transfusion medicine, ensuring patient safety, compatibility and optimized outcomes. This discipline has evolved from basic blood typing assays to advanced molecular platforms that detect infectious agents, immune responses and genetic markers. In a landscape characterized by rising demand for precision medicine and stringent regulatory requirements, diagnostics providers face the dual challenge of delivering rapid, reliable results while managing cost pressures and complex supply chains. This executive summary synthesizes current industry dynamics, highlights transformative shifts, examines the implications of recent trade policies and distills actionable recommendations. By weaving together segmentation analysis, regional nuances and competitive intelligence, it offers decision-makers a clear view of the strategic levers shaping the blood transfusion diagnostics market today.

Transformative Shifts Reshaping Blood Transfusion Diagnostics

Over the past decade, blood transfusion diagnostics has undergone transformative shifts driven by technological innovation and changing patient needs. The integration of high-throughput nucleic acid amplification technologies has accelerated the detection of viral contaminants, while multiplex serological assays now enable simultaneous screening for multiple pathogens. Digital health platforms and cloud-based data management solutions enhance traceability and regulatory compliance throughout the donor-to-recipient continuum. In addition, the rise of point-of-care testing is empowering smaller hospitals and mobile blood drives to deliver critical diagnostics in remote settings.

Simultaneously, increased focus on personalized transfusion protocols is prompting the adoption of leukocyte-reduced and HLA-matched products, supported by advanced immunogenetic testing. Regulatory agencies worldwide are harmonizing guidelines for pathogen reduction technologies and post-transfusion surveillance, prompting manufacturers to innovate under unified quality frameworks. As a result, supply chains are becoming more collaborative, with strategic alliances emerging between reagent suppliers, instrument vendors and digital health specialists. These collective forces are redefining value propositions, steering the market toward integrated solutions that combine diagnostics, data analytics and patient-centric services.

Cumulative Impact of United States Tariffs in 2025 on Diagnostics Supply Chain

The imposition of additional tariffs in the United States throughout 2025 has reverberated across the blood transfusion diagnostics supply chain. Key reagents and assay kits sourced from international manufacturers now encounter higher duty rates, directly influencing product pricing and forcing end users to reassess procurement strategies. Diagnostic laboratories and hospital networks are absorbing a portion of these incremental costs, yet many are also exploring domestic sourcing alternatives to mitigate exposure to fluctuating tariffs.

Moreover, the tariff-driven cost escalation has accelerated discussions around localized manufacturing. Several diagnostic manufacturers have announced plans to expand U.S.-based production facilities, aiming to bypass trade barriers and secure more predictable cost structures. Meanwhile, distributors are reevaluating inventory management practices, prioritizing buffer stocks of critical components to avoid potential disruptions. In parallel, end users are negotiating bundled contracts that include service agreements and volume discounts to offset the tariff impact, underscoring the importance of strategic procurement in maintaining continuity of operations.

Key Segmentation Insights for Market Dynamics

Analyzing market segments provides nuanced clarity on demand drivers and growth opportunities. Based on the type of diagnostics, the landscape spans complete blood count tests and crossmatching assays, alongside nucleic acid amplification tests and serological tests, while donor screening tests-encompassing both pre-donation and post-donation evaluations-play a pivotal role in donor safety and infectious disease surveillance. Shifting focus to end users, a diverse network of academic and research institutes conducts foundational investigations, blood banks prioritize large-scale donor processing, diagnostic laboratories manage high-throughput assay workflows and hospitals, segmented into private and public establishments, integrate testing into clinical care pathways.

Considering component types, the market dissects into cryoprecipitated antihemophilic factor, plasma products and cellular units such as platelets and red blood cells. Plasma subdivisions include fresh frozen plasma and plasma exchange applications, whereas platelet therapies differentiate between random donor platelets and single donor platelets. Within red blood cells, product variants like leukocyte-reduced units and packed red blood cells address safety and storage efficiency. From a test types perspective, advanced screening protocols for emerging pathogens such as West Nile virus and Zika virus coexist with autoimmune and genetic assays, routine testing platforms, confirmatory hepatitis and HIV analyses-differentiating between Hepatitis B versus C or HIV-1 versus HIV-2-and specialized testing services.

Further refinement arises through technology segmentation, where innovations like clustered regularly interspaced short palindromic repeats, loop-mediated isothermal amplification, mass spectrometry, microarrays and polymerase chain reaction constitute the core analytical toolkit. Finally, patient demographics inform demand patterns, with adult, geriatric and pediatric populations each exhibiting distinct transfusion requirements and safety thresholds. By aligning product development and marketing strategies with these layered segmentations, industry stakeholders can pinpoint white space opportunities and optimize resource allocation across the diagnostics value chain.

Regional Trends Driving Market Growth and Adoption

Regional dynamics significantly influence innovation trajectories and adoption rates. In the Americas, a robust network of transplant centers and well-established blood donation programs drives sustained interest in advanced immunogenetic testing and pathogen reduction solutions. North American regulatory harmonization encourages cross-border clinical collaborations, while Latin American markets are gradually investing in infrastructure upgrades to meet evolving standards. Europe, the Middle East and Africa present a mosaic of mature markets with stringent quality regulations alongside emerging regions focused on cost-effective diagnostics, prompting tiered portfolio strategies that balance high-end molecular platforms with simpler serological assays. In the Asia-Pacific, rapid healthcare modernization and expanding government initiatives to enhance transfusion safety are accelerating procurement of point-of-care devices, nucleic acid amplification systems and digital data management tools. Cross-regional partnerships and technology transfer agreements are likewise fostering knowledge exchange and accelerating clinical validation efforts worldwide.

Competitive Landscape and Leading Company Strategies

The competitive arena features a diversified mix of legacy players and nimble innovators. Industry titans such as Abbott Laboratories and Becton, Dickinson and Company leverage global manufacturing footprints and broad product portfolios, while specialized firms like BAG Diagnostics GmbH and Quotient Suisse SA focus on niche assay development and customized reagent solutions. Danaher Corporation and Thermo Fisher Scientific Inc. continue to expand through acquisitions, integrating comprehensive instrumentation suites with consumables and informatics platforms. F. Hoffmann-La Roche AG and Merck KGaA prioritize R&D investments in next-generation sequencing and mass spectrometry applications, whereas Bio-Rad Laboratories Inc. and Fujirebio by H.U. Group enhance their competitive edge via strategic partnerships targeting emerging pathogens.

Regional footprints also differentiate market leaders. Grifols S.A. and Immucor Inc. maintain strong positions in immunohematology and blood typing, backed by extensive distribution networks. Laboratory Corporation of America Holdings emphasizes centralized testing services with high-volume throughput, and QuidelOrtho Corporation directs efforts toward rapid diagnostic assays. Werfen S.A. combines point-of-care coagulation monitoring with a growing infectious disease portfolio. Collectively, these 15 prominent companies shape the blood transfusion diagnostics ecosystem through sustained innovation, targeted alliances and agile responses to evolving regulatory and trade environments.

Actionable Recommendations for Industry Leaders

Industry leaders should capitalize on emerging opportunities by embracing a multi-faceted strategic playbook. First, investing in modular manufacturing and regional production hubs will mitigate tariff exposure and enhance supply chain resilience. Second, forging cross-sector partnerships-linking diagnostics providers with digital health startups, academic centers and clinical networks-can accelerate technology adoption and streamline regulatory approvals. Third, customizing product portfolios to address differentiated end-user needs across academic research, blood banks, diagnostic laboratories and both private and public hospitals will bolster market penetration and foster long-term customer loyalty.

Furthermore, prioritizing rapid innovation cycles for advanced screening technologies and next-generation molecular platforms will satisfy growing demand for predictive diagnostics and real-time surveillance. In parallel, adopting service-based business models that bundle assay kits with training, maintenance and data analytics will facilitate recurring revenue streams and strengthen client relationships. Lastly, leveraging patient demographic insights to develop specialized testing protocols for adult, geriatric and pediatric populations will position organizations as comprehensive solution providers capable of addressing the full spectrum of transfusion safety challenges.

Conclusion: Embracing Innovation and Resilience

In conclusion, the blood transfusion diagnostics market stands at the crossroads of technological advancement, regulatory evolution and shifting economic policies. Organizations that strategically align their R&D investments with emerging molecular and digital health tools, while simultaneously adapting supply chain strategies to address tariff impacts, will secure competitive advantage. Leveraging detailed segmentation insights and regional market trends enables stakeholders to tailor offerings and penetrate high-growth areas. As the industry moves toward integrated diagnostics and data-driven decision support, collaboration across the value chain will prove indispensable in delivering safer, more efficient transfusion outcomes and sustaining long-term growth.

Market Segmentation & Coverage

This research report categorizes the Blood Transfusion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Complete Blood Count Tests
  • Crossmatching Tests
  • Donor Screening Tests
    • Post-Donation Tests
    • Pre-Donation Tests
  • Nucleic Acid Amplification Tests
  • Serological Tests
  • Academic and Research Institutes
  • Blood Banks
  • Diagnostic Laboratories
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Cryoprecipitated AHF
  • Plasma
    • Fresh Frozen Plasma
    • Plasma Exchange
  • Platelets
    • Random Donor Platelets
    • Single Donor Platelets
  • Red Blood Cells
    • Leukocyte-Reduced RBCs
    • Packed RBCs
  • Advanced Screening
    • West Nile Virus
    • Zika Virus
  • Autoimmune and Genetic Tests
  • Confirmatory Testing
    • Hepatitis
      • Hepatitis B
      • Hepatitis C
    • HIV
      • HIV-1
      • HIV-2
  • Routine Testing
  • Specialized Testing
  • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • Loop-Mediated Isothermal Amplification (LAMP)
  • Mass Spectrometry
  • Microarray
  • Polymerase Chain Reaction (PCR)
  • Adult
  • Geriatric
  • Pediatric

This research report categorizes the Blood Transfusion Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Blood Transfusion Diagnostics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • BAG Diagnostics GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Fujirebio by H.U. Group
  • Grifols, S.A.
  • Immucor, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • QuidelOrtho Corporation
  • Quotient Suisse SA
  • Thermo Fisher Scientific Inc.
  • Werfen, S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Transfusion Diagnostics Market, by Type of Diagnostics
8.1. Introduction
8.2. Complete Blood Count Tests
8.3. Crossmatching Tests
8.4. Donor Screening Tests
8.4.1. Post-Donation Tests
8.4.2. Pre-Donation Tests
8.5. Nucleic Acid Amplification Tests
8.6. Serological Tests
9. Blood Transfusion Diagnostics Market, by End User
9.1. Introduction
9.2. Academic and Research Institutes
9.3. Blood Banks
9.4. Diagnostic Laboratories
9.5. Hospitals
9.5.1. Private Hospitals
9.5.2. Public Hospitals
10. Blood Transfusion Diagnostics Market, by Component Type
10.1. Introduction
10.2. Cryoprecipitated AHF
10.3. Plasma
10.3.1. Fresh Frozen Plasma
10.3.2. Plasma Exchange
10.4. Platelets
10.4.1. Random Donor Platelets
10.4.2. Single Donor Platelets
10.5. Red Blood Cells
10.5.1. Leukocyte-Reduced RBCs
10.5.2. Packed RBCs
11. Blood Transfusion Diagnostics Market, by Test Types
11.1. Introduction
11.2. Advanced Screening
11.2.1. West Nile Virus
11.2.2. Zika Virus
11.3. Autoimmune and Genetic Tests
11.4. Confirmatory Testing
11.4.1. Hepatitis
11.4.1.1. Hepatitis B
11.4.1.2. Hepatitis C
11.4.2. HIV
11.4.2.1. HIV-1
11.4.2.2. HIV-2
11.5. Routine Testing
11.6. Specialized Testing
12. Blood Transfusion Diagnostics Market, by Technology
12.1. Introduction
12.2. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
12.3. Loop-Mediated Isothermal Amplification (LAMP)
12.4. Mass Spectrometry
12.5. Microarray
12.6. Polymerase Chain Reaction (PCR)
13. Blood Transfusion Diagnostics Market, by Patient Demographics
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Americas Blood Transfusion Diagnostics Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Blood Transfusion Diagnostics Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Blood Transfusion Diagnostics Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. BAG Diagnostics GmbH
17.3.3. Becton, Dickinson and Company
17.3.4. Bio-Rad Laboratories, Inc.
17.3.5. Danaher Corporation
17.3.6. F. Hoffmann-La Roche AG
17.3.7. Fujirebio by H.U. Group
17.3.8. Grifols, S.A.
17.3.9. Immucor, Inc.
17.3.10. Laboratory Corporation of America Holdings
17.3.11. Merck KGaA
17.3.12. QuidelOrtho Corporation
17.3.13. Quotient Suisse SA
17.3.14. Thermo Fisher Scientific Inc.
17.3.15. Werfen, S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BLOOD TRANSFUSION DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. BLOOD TRANSFUSION DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD TRANSFUSION DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BLOOD TRANSFUSION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BLOOD TRANSFUSION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD TRANSFUSION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPLETE BLOOD COUNT TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY POST-DONATION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRE-DONATION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CRYOPRECIPITATED AHF, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY FRESH FROZEN PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RANDOM DONOR PLATELETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SINGLE DONOR PLATELETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LEUKOCYTE-REDUCED RBCS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PACKED RBCS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY WEST NILE VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE AND GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV-1, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV-2, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ROUTINE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SPECIALIZED TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR), BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP), BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 111. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 112. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 113. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 117. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 118. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 119. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 120. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 121. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 122. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 123. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 124. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. CANADA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 188. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 189. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 190. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 194. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 195. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 196. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 197. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 198. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 199. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 200. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 201. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 202. CHINA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 203. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 204. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 205. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 209. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 210. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 211. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 212. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 213. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 214. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 215. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 216. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. INDIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 219. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 233. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 234. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 235. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 239. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 240. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 241. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 242. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 243. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 244. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 246. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. JAPAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 248. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 249. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 275. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 279. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 280. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 284. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 285. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 287. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 288. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 293. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 294. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 2018-2030 (USD MILLION)
TABLE 295. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COMPONENT TYPE, 2018-2030 (USD MILLION)
TABLE 298. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLASMA, 2018-2030 (USD MILLION)
TABLE 299. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PLATELETS, 2018-2030 (USD MILLION)
TABLE 300. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RED BLOOD CELLS, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ADVANCED SCREENING, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HIV, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 308. TAIWAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 309. TAIWAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONOR SCREENING TESTS, 201

Companies Mentioned

  • Abbott Laboratories
  • BAG Diagnostics GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Fujirebio by H.U. Group
  • Grifols, S.A.
  • Immucor, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • QuidelOrtho Corporation
  • Quotient Suisse SA
  • Thermo Fisher Scientific Inc.
  • Werfen, S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Blood Transfusion Devices Market - Global Forecast to 2030 - Product Image

Blood Transfusion Devices Market - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Blood Transfusion Diagnostics Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Blood Transfusion Diagnostics Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 158 Pages
  • Global
From
Blood Transfusion Diagnostics - Global Strategic Business Report - Product Image

Blood Transfusion Diagnostics - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
Blood Transfusion Diagnostics Market Report 2025 - Product Image

Blood Transfusion Diagnostics Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Blood Transfusion Market: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Blood Transfusion Market: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 310 Pages
  • Global
From

About the Transfusion Diagnostics Market

The Transfusion Diagnostics market is a segment of the In Vitro Diagnostics (IVD) industry. It focuses on the development and production of diagnostic tests used to detect and monitor blood-borne diseases, such as HIV, hepatitis, and syphilis. These tests are used to ensure the safety of blood transfusions and to monitor the health of blood donors. Transfusion Diagnostics tests are used in hospitals, blood banks, and other healthcare settings. The Transfusion Diagnostics market is driven by the increasing demand for safe and reliable blood transfusions, as well as the need for improved patient safety. Additionally, the development of new technologies, such as molecular diagnostics, has enabled the development of more accurate and sensitive tests. Some companies in the Transfusion Diagnostics market include Abbott, Bio-Rad Laboratories, Becton Dickinson, Ortho Clinical Diagnostics, and Siemens Healthineers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.